Shares of Tiziana Life Sciences ticked up 3.8% in pre-market trading to $1.09 after the company announced it dosed the final patient in its Phase 2 trial of an intranasal antibody therapy for early Alzheimer's disease. The placebo-controlled study is now fully enrolled, with topline data anticipated in Q1 2027. For a micro-cap biotech burning cash with no revenue, the news locks in a timeline — but the real test hasn't started yet.
The Trial Targets a Gap Big Pharma Hasn't Closed. The study tests foralumab — delivered as a nasal spray — both alone and alongside FDA-approved amyloid-clearing drugs like lecanemab and donanemab. That matters because brain-imaging data have shown persistent neuroinflammation in Alzheimer's patients even after amyloid plaque reduction with lecanemab. If foralumab can calm that residual brain inflammation, it could position Tiziana as a partner or acquisition target in a global Alzheimer's drug market valued at roughly $8.5 billion in 2025 and projected to reach $13 billion by 2034.
A Second Data Readout Could Come Even Sooner. Alzheimer's isn't Tiziana's only bet. Topline data from its Phase 2 multiple sclerosis trial — which enrolled 48 patients — were expected in late Q3 or early Q4 2026, with presentation planned at the ACTRIMS/ECTRIMS conference in Toronto this October. A positive MS readout could validate the core technology ahead of the Alzheimer's results, giving investors two shots on goal within months.
The Cash Question Looms Large. Tiziana held just $3.72 million in cash against $106,000 in debt as of recent filings.
The company has historically funded operations through repeated stock sales that dilute existing shareholders. With a market cap of roughly $140 million and operating cash outflows of about $13 million a year , the math suggests fresh capital will be needed well before any approval revenue arrives. BTIG initiated coverage in September with a Buy rating and a $7 price target — implying over 650% upside — but that bet hinges entirely on clinical success.
Bottom Line: Completing enrollment eliminates one risk — the trial will produce data. But Tiziana still faces the classic micro-cap biotech dilemma: a thin balance sheet, binary clinical outcomes, and a stock price that can move violently in either direction once results land in early 2027.